Medicinal Cannabis for Pain, Sleep, Anxiety and PTSD: What the Evidence Can Actually Support

A promising treatment is not the same as a proven outcome

Medicinal cannabis sits at the intersection of symptom relief, rapidly changing prescribing and unsettled evidence. Some people report meaningful improvement. But products vary in cannabidiol (CBD), tetrahydrocannabinol (THC), dose and route, and most medicinal cannabis products supplied in Australia remain unapproved therapeutic goods. A credible review therefore starts with the exact product and intended outcome.

The question is not “does cannabis work?” It is: for this condition, formulation and patient, is there evidence of a clinically meaningful benefit—and does that benefit translate into better sleep, activity, work capacity or quality of life?

Chronic pain and physical injury

The TGA’s chronic non-cancer pain guidance describes limited efficacy in some patients and generally modest average effects. It also notes uncertainty, variable study quality and adverse events. Evidence is more developed for some neuropathic pain settings than for common musculoskeletal injuries, arthritis or fibromyalgia.

In a claim, pain-score change should not be treated as the only outcome. Reduced opioid burden, improved sleep, participation in rehabilitation and physical function may be relevant—but each needs to be demonstrated in the records rather than assumed.

Sleep, anxiety and PTSD

Sleep can improve when pain or distress improves, but sedation is not the same as restorative sleep. For anxiety and PTSD, dose and cannabinoid profile matter. THC can worsen anxiety, cognition or psychotic symptoms in susceptible people, while evidence for CBD-containing products remains condition- and dose-specific. Marketing claims commonly run ahead of clinical evidence.

A medication evidence review should separate symptom reports from diagnostic outcomes, identify concurrent psychological treatment and test whether benefits persisted beyond the early treatment period.

Safety, interactions and function

Relevant risks include fatigue, sedation, dizziness, cognitive change, psychiatric effects and drug interactions. THC-containing products also create major driving and safety-sensitive work issues. Even CBD-only products may cause fatigue or interact with other medicines. Combining cannabinoids with alcohol, opioids, benzodiazepines or other sedatives can increase functional risk.

The balanced conclusion may be favourable, unfavourable or mixed. A person can experience genuine symptom relief while also losing the ability to drive, perform safety-critical duties or satisfy workplace drug policies. Both sides of that equation belong in the opinion.

Frequently asked questions